Antiviral effect of recombinant equine interferon-gamma on several equine viruses.
Recombinant equine interferon-gamma (reIFN-gamma) was prepared using a baculovirus expression system and its antiviral activity was investigated using several equine viruses. The reIFN-gamma suppressed the replication of all equine viruses used in the present experiment in horse cell cultures, but did not affect the growth of host cells at concentrations of less than 1000 u/ml. A strong antiviral effect was observed, especially against RNA viruses. Equine picornavirus, equine rhinovirus and equine arteritis virus could not be propagated at all in 100 u/ml reIFN-gamma when 100 TCID(50) of infective viruses was inoculated to cultivated horse cells. DNA viruses, equine herpesvirus types 1, 2, 3 and 4 and equine adenovirus, were less sensitive to reIFN-gamma but their growth became less than 1/100 in the cells treated with 100 u/ml reIFN-gamma compared to untreated cells. The antiviral effects were decreased in the cells of heterologous species and more than 1000 u/ml reIFN-gamma was required to induce an antiviral effect.
Sentsui
Hiroshi
H
National Institute of Animal Health, 3-1-5, Kannondai, Tsukuba, Ibaraki 305-0856, Japan. Electronic address: sentusi.hiroshi@nihon-u.ac.jp.
Wu
Donglai
D
National Institute of Animal Health, 3-1-5, Kannondai, Tsukuba, Ibaraki 305-0856, Japan; National Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, CAAS, Harbin 15000, China.
Murakami
Kenji
K
National Institute of Animal Health, 3-1-5, Kannondai, Tsukuba, Ibaraki 305-0856, Japan.
Kondo
Takashi
T
Epizootic Research Center, Equine Research Institute, Japan Racing Association, 1400-4, Shiba, Shimotsuke, Tochigi 329-0412, Japan.
Matsumura
Tomio
T
Epizootic Research Center, Equine Research Institute, Japan Racing Association, 1400-4, Shiba, Shimotsuke, Tochigi 329-0412, Japan.
D000256:Adenoviridae / Q000187:drug effects*; D000524:Alphavirus / Q000187:drug effects*; D000818:Animals; D000998:Antiviral Agents / Q000009:adverse effects / Q000494:pharmacology*; D005537:Aphthovirus / Q000187:drug effects*; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D007240:Equartevirus / Q000187:drug effects*; D004861:Herpesvirus 1, Equid / Q000187:drug effects*; D004858:Herpesvirus 3, Equid / Q000187:drug effects*; D023141:Herpesvirus 4, Equid / Q000187:drug effects*; D006734:Horse Diseases / Q000188:drug therapy / Q000821:virology; D006736:Horses / Q000821:virology; D007371:Interferon-gamma / Q000009:adverse effects / Q000494:pharmacology*; D010849:Picornaviridae / Q000187:drug effects*; D011994:Recombinant Proteins; D018144:Rhadinovirus / Q000187:drug effects*; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D011994:Recombinant Proteins; D007371:Interferon-gamma